Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003

PharmacoEconomics

Volumn 24, Issue 9, 2006, Pages 891-902

  Lee, Yue Chune ^a   Yang, Ming Chin ^b   Huang, Yu Tung ^a   Liu, Chien Hsiang ^c   Chen, Sun Bing ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Bureau of National Health Insurance Taiwan   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE RESPIRATORY TRACT DISEASE; ARTICLE; BUDGET; CHINESE; CONTROLLED STUDY; COST CONTROL; DENTIST; DISEASE SEVERITY; DRUG COST; EPIDEMIC; HEALTH PROGRAM; HOSPITAL PATIENT; HUMAN; INTERVENTION STUDY; NATIONAL HEALTH INSURANCE; OUTPATIENT DEPARTMENT; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; TAIWAN; TIME SERIES ANALYSIS;

COST CONTROL; ECONOMICS, PHARMACEUTICAL; HUMANS; NATIONAL HEALTH PROGRAMS; SEASONS; TAIWAN;

EID: 33748353843     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624090-00006     Document Type: Article

References (20)

1. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff 2003; 22 (3): 61-76
2. Huang WF, Chiang HC. Pharmaceutical benefit scheme and cost containment in Taiwan's National Health Insurance. J Pharm Finance Econ Policy 2003; 12 (2): 133-49
3. Chiang TL. Taiwan's 1995 health care reform. Health Policy 1997; 39 (3): 225-39
4. Lu JFR, Hsiao WC. Does Universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff 2003; 22 (3): 77-88
5. McGuire TG. Physician agency. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. New York: Elsevier, 2000: 461-536
6. Zweifel P, Manning WG. Moral hazard and consumer incentives in health care. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. New York: Elsevier, 2000: 409-60
7. Dickson M. Paying for prescriptions in Europe. In: OECD: Health policy studies no. 4. Health: quality and choice. Paris: OECD, 1994: 83-109
8. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21 (2): 89-103
9. Saltman R, Bankauskaite V, Vrangbaek K. Decentralization in health care: strategies and outcomes [online]. Available from URL: http://www.who.dk/ observatory/Studies/20031112_1.htm [Accessed 2005 Feb 23]
10. Box GEP, Taio GC. Intervention analysis with applications to economic and environmental problems. J Am Stat Assoc 1975; 70 (349): 70-9
11. Box GEP, Jenkins GM, Reinsel GC. Time series analysis: forecasting and control. 3rd ed. Upper Saddle River (NJ): Prentice Hall, 1994
12. Liu LM. Analysis of time series with calendar effects. Manage Sci 1980; 26 (1): 106-12
13. Chang HJ, Huang N, Lee CH, et al. The impact of the SARS epidemic on the utilization of medical services: SARS and the fear of SARS. Am J Public Health 2004; 94 (4): 562-4
14. Huang WF, Lo KL, Chen LW. Comparison of Taiwan's NHI drug price and international drug price [in Chinese]. Chin J Public Health 1998; 17 (3): 265-72
15. Abramson R, Harrington CA, Missmar R, et al. Generic drug cost containment in Medicaid: lessons from five state MAC programs. Health Care Financ Rev 2004; 25 (3): 25-34
16. Kanavos P, Reinhardt U. Reference pricing for drugs: is it recompatible with US health care? Health Aff 2003; 22 (3): 16-30
17. Giuliani F, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998; 44 (1): 73-85
18. Delnoij D, Brenner G. Importing budget systems from other countries: what can we learn from the German drug budget and British GP fundholding? Health Policy 2000; 52 (3): 157-69
19. Harris CM, Scrivener G. Fundholders' prescribing costs: the first five years. BMJ 1996; 313 (7071): 1531-4
20. Liu SZ, Romeis JC. Changes in drug utilization following the outpatient prescription drug cost-sharing program-evidence from Taiwan's elderly. Health Policy 2004; 68 (3): 277-87